Novartis Entresto receives FDA approval for paediatric heart failure, helping to address critical unmet need for treatment options

1 October 2019 - Entresto is now approved for the treatment of paediatric patients aged 1 year and older with symptomatic ...

Read more →

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels

27 September 2019 - The U.S. FDA today approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis ...

Read more →

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma

12 September 2019 - GlaxoSmithKline today announced that the US FDA has approved Nucala (mepolizumab) for use in children as young ...

Read more →

GeneTx and Ultragenyx announce orphan drug designation and rare paediatric disease designation for GTX-102

3 September 2019 - GeneTx Biotherapeutics and Ultragenyx today announced that the U.S. FDA has granted orphan drug designation and rare ...

Read more →

Promoting paediatric drug research and labelling — outcomes of legislation

28 August 2019 - Congress has modified regulations of the FDA to promote research assessing the efficacy and safety of drugs ...

Read more →

Teva launches generic version of EpiPen for young children

20 August 2019 - Teva Pharmaceutical Industries on Tuesday made its generic version of Mylan’s EpiPen for young children available in ...

Read more →

This drug will save children’s lives. It costs $2 million.

13 August 2019 - Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments. ...

Read more →

FDA issues draft guidance regarding clinical trial design for newborns

31 July 2019 - Today, the U.S. Food and Drug Administration issued the draft guidance, General Clinical Pharmacology Considerations for Neonatal ...

Read more →

Ultragenyx announces submission of new drug application to FDA for UX007 (triheptanoin) for treatment of long-chain fatty acid oxidation disorders

1 August 2019 - Ultragenyx today announced that it has submitted to the U.S. FDA a new drug application for UX007 ...

Read more →

Momenta Pharmaceuticals announces fast track designation for M281 (nipocalimab) in haemolytic disease of the foetus and newborn

30 July 2019 - Momenta Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for M281, Momenta’s ...

Read more →

FDA updates draft guidance on rare paediatric disease priority review voucher program

29 July 2019 - The U.S. FDA today issued a revised draft guidance, Rare Paediatric Disease Priority Review Vouchers – ...

Read more →

LifeMax receives rare paediatric disease designation for LM-030 for the treatment of Netherton syndrome

18 July 2019 - LifeMax Laboratories today announced that the FDA granted rare paediatric disease designation to LM-030, an investigational therapy ...

Read more →

LogicBio Therapeutics receives rare paediatric disease designation for LB-001 for the treatment of methylmalonic acidaemia

16 July 2019 -  LogicBio Therapeutics today announced the U.S. FDA has granted rare paediatric disease designation to LB-001, a ...

Read more →

FDA approves Katerzia, the first and only amlodipine oral suspension for paediatric patients 6 years of age and older

10 July 2019 - Azurity Pharmaceuticals announced today that the U.S. FDA has approved Katerzia (amlodipine) 1 mg/mL oral suspension, ...

Read more →

FDA approves Botox (onabotulinumtoxinA) for paediatric patients with upper limb spasticity

21 June 2019 - Approval marks 10th Botox therapeutic indication in its 30th anniversary year. ...

Read more →